Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years

NCT06891950 is registered in ClinicalTrials.gov with Butantan Institute as lead sponsor.

NCT NCT06891950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06891950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years
Lead sponsor
Butantan Institute
Phase
Phase 3
Overall status
Recruiting
Start date
March 3, 2026
Completion date
October 31, 2027
Enrollment
997 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dengue